Details for Patent: 8,835,501

Which drugs does patent 8,835,501 protect, and when does it expire?

Patent 8,835,501 protects BELEODAQ and is included in one NDA.

This patent has forty-one patent family members in twenty-six countries.

Summary for Patent: 8,835,501

Title:	Pharmaceutical formulations of HDAC inhibitors
Abstract:	This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
Inventor(s):	Bastin; Richard J. (Waterford, IE), Hughes; Nicholas J. (Swindon, GB)
Assignee:	TopoTarget UK Limited (Abingdon, Oxfordshire, GB)
Application Number:	11/913,191
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,835,501
Patent Claim Types: see list of patent claims	Composition; Compound; Formulation; Dosage form; Device;

Drugs Protected by US Patent 8,835,501

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Acrotech Biopharma	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 8,835,501

PCT Information
PCT Filed	May 11, 2006	PCT Application Number:	PCT/GB2006/001737
PCT Publication Date:	November 16, 2006	PCT Publication Number:	WO2006/120456

International Family Members for US Patent 8,835,501

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E542527
Australia	2006245495
Brazil	PI0610128
Canada	2606598
China	101189003
China	102579417
Cyprus	1112498